Baricitinib, a JAK1/JAK2 inhibitor, caused a reduction in lung infiltration by inflammatory cells, including neutrophils, and, consequently, controlled lung pathology in a model of COVID-19 (68). This evidence concerns the gene JAK2 and COVID-19.